Axial Spondyloarthritis | Disease Landscape & Forecast | G7 | 2022

The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen / Pfizer’s Enbrel, AbbVie’s Humira, Janssen’s Remicade and Simponi / Simponi Aria, and UCB’s Cimzia); and IL-17 inhibitors (Novartis’s Cosentyx and Eli Lilly’s Taltz). The TNF-α inhibitors are the most widely prescribed biologics for AxSpA that is refractory to nonsteroidal anti-inflammatory drugs (NSAIDs). However, these agents face a competitive threat, both from the launch of cost-effective biosimilars and from the growing IL-17 class. In 2019, the FDA approved Cimzia for nonradiographic (nr)-AxSpA, marking the first FDA approval for this subpopulation, followed by both IL-17 inhibitors in June 2020. The recent approval of novel oral targeted therapies—JAK inhibitors (Pfizer’s Xeljanz and AbbVie’s Rinvoq)—for ankylosing spondylitis (AS) and the impending entry of an additional IL-17 inhibitor (UCB’s bimekizumab) will further shift market dynamics.

Questions answered:

  • How large is the treatable AxSpA population, and how will diagnosis / drug-treatment rates change over time?
  • What are interviewed experts’ insights on current treatment options for AS and nr-AxSpA? What clinical needs remain unfulfilled?
  • What pipeline products are the most promising, and what key therapies are in early-phase development?
  • What are interviewed experts’ opinions of the use of Xeljanz and Rinvoq for AS? What sales / uptake could JAK inhibitors secure in AxSpA?
  • What are the drivers of and constraints in the AxSpA therapy market, and how will the market evolve over the forecast period?

Content highlights:

Geographies: United States, EU5, Japan

Primary research: Approximately 30 country-specific interviews with thought-leading rheumatologists; supported by survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed prevalent cases of AxSpA by country; AS and nr-AxSpA subpopulations.

Forecast: 10-year, annualized, drug-level sales and patient share of key AxSpA therapies through 2031, segmented by brands / generics and epidemiological subpopulations

Emerging therapies: Phase III: 1 drug; Phase II: 2 drugs

Product description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Login to access report

launch Related Market Assessment Reports